The National Research Council of Canada and Aspect Biosystems are collaborating to develop a 3D model of the blood-brain barrier.
Aspect is presenting preclinical data from recent studies focused on developing a bioprinted meniscus tissue for surgical implantation.
The Maastricht Institute for Technology-Inspired Regenerative Medicine will develop kidney tissue using an RX1™ Bioprinting Platform.
Aspect CEO and CSO visit Hong Kong for the first time to speak at the Heart Regeneration Symposium and host a seminar.
Government of Canada invests nearly $20M in top British Columbia companies in 2018.
We are attending, exhibiting, and speaking at Biofabrication, Oct 28-31, 2018 in Würzburg, Germany.
Paul joins Aspect following management roles at Schneider Electric, GE, and PMC-Sierra.
BIOTECanada Gold Leaf Award Winner for Emerging Company of the Year 2018: Aspect Biosystems.
Spiro joins Aspect following his role as Biology Director at GlaxoSmithKline and as a Faculty Member at Northwestern University.
"Aspect Biosystems: Building a Global Discovery Ecosystem from Right Here in Canada" - BIOTECanada insights Magazine, Fall 2018
Aspect Biosystems announces collaboration with multinational JSR Corporation to develop human liver tissue.
We attended and spoke at BioJapan & Regenerative Medicine Japan, Oct 10-12, 2018 in Yokohama, Japan.
Our team is headed to Kyoto, Japan for TERMIS World Congress Sep 4-7, 2018.
UBC Applied Science profiles our CEO to learn how his focus shifted from academic to industry.
The Stem Cell Networks appoints Tamer Mohamed, CEO of Aspect Biosystems, to its Board of Directors
Our collaborators from the Frampton Lab at Dalhousie University are presenting research they performed in collaboration with Aspect.